A Randomized Controlled Trial Comparing Budesonide and Mometasone Furoate Nasal Spray in the Treatment of Chronic Rhinosinusitis with Nasal Polyposis: Evaluating Symptom Scores and Quality of Life

Background. Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a highly debilitating inflammatory condition that affects many people and considerably reduces their quality of life. The mainstay of medical therapy are the intranasal corticosteroids and among them the most commonly used are budesonide and mometasone furoate. They have been used for a long time; however, only few studies have compared their efficacy. Objective. To compare the efficacy of budesonide and mometasone furoate nasal sprays for the treatment of CRSwNP with validated patient-reported outcome measures in a randomized controlled trial. Material and methods. This was a two arm parallel randomized controlled clinical trial on 100 adults with CRSwNP who were randomly allocated to budesonide and mometasone furoate nasal spray. SNOT-22, TNSS, and RSDI symptom severity scales were used at the baseline and follow-up visits to assess the symptom severity. Results. The results demonstrated significant changes in SNOT-22, TNSS, and RSDI scores in both treatment groups from week 0 to 4. Nevertheless the mometasone furoate group showed a superior overall symptom control and quality of life; improvement in SNOT-22 and RSDI and hence a better therapeutic effect over the budesonide group. Conclusion. Studies have shown that both budesonide and mometasone furoate nasal sprays were efficacious in the treatment of sinonasal symptoms, nasal polyps-specific symptoms and quality of life in CRSwNP patients, however, mometasone furoate demonstrated overall better group effects on sinonasal symptoms and quality of life at 1 month follow-up post treatment due to its higher potency and longer duration of action.